Cargando…

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab

As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinfla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gentile, Giorgio, Davies, Rebecca, Manfreda, Valeria Maria, Ul Abideen, Zain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798428/ https://www.ncbi.nlm.nih.gov/pubmed/33419750 http://dx.doi.org/10.1136/bcr-2020-238210

Ejemplares similares

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
por: Toniati, Paola, et al.
Publicado: (2020)

O03 A case of hyperinflammatory COVID-19 that responded to tocilizumab therapy
por: Biddle, Kathryn, et al.
Publicado: (2020)

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort()
por: Corominas, Hèctor, et al.
Publicado: (2021)

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
por: Rodríguez-Baño, Jesús, et al.
Publicado: (2021)

Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases
por: Chochoł-Labun, Joanna, et al.
Publicado: (2021)

First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID‐19 in an allogeneic stem cell transplant patient
por: Fordham, Nicholas, et al.
Publicado: (2020)

Defining the scourge of COVID-19 hyperinflammatory syndrome
por: Cron, Randy Q, et al.
Publicado: (2020)

Drugs for paediatric hyperinflammatory syndromes
por: Hon, Kam Lun, et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Haemophagocytic lymphohisticytosis—an underrecognized hyperinflammatory syndrome
por: Hutchinson, Matthew, et al.
Publicado: (2019)

Infection-Triggered Hyperinflammatory Syndromes in Children
por: Rossano, Martina, et al.
Publicado: (2022)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Acute fibrinous and organizing pneumonia masquerading as a lower respiratory tract infection: a case report and review of the literature
por: Akhtar, Aftab, et al.
Publicado: (2015)

Hyperinflammatory Syndrome in Children Associated With COVID-19: Need for Awareness
por: Bhat, Chandrika S., et al.
Publicado: (2020)

Defining COVID-19-associated hyperinflammatory syndrome in specific populations
por: Webb, Brandon J
Publicado: (2021)

The Techniques of Blood Purification in the Treatment of Sepsis and Other Hyperinflammatory Conditions
por: Berlot, Giorgio, et al.
Publicado: (2023)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

Hyperinflammatory Response in COVID-19: A Systematic Review
por: Silva, Marcos Jessé Abrahão, et al.
Publicado: (2023)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

COVID-19 in Children: A Review and Parallels to Other Hyperinflammatory Syndromes
por: Hobbs, Charlotte V., et al.
Publicado: (2020)

Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome
por: Michotte, Naomi, et al.
Publicado: (2021)

Post-Infectious COVID-19-Associated Hyperinflammatory Syndrome in An Older Patient
por: Famularo, Giuseppe, et al.
Publicado: (2022)

How Immunosenescence and Inflammaging May Contribute to Hyperinflammatory Syndrome in COVID-19
por: Müller, Ludmila, et al.
Publicado: (2021)

Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections
por: Minihan, B., et al.
Publicado: (2022)

Successful high flow nasal cannula therapy for severe COVID-19 pneumonia is associated with tocilizumab use
por: Ouissa, R., et al.
Publicado: (2022)

Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19
por: Koh, June-Young, et al.
Publicado: (2023)

Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Severe Dengue( )
por: Vuong, Nguyen Lam, et al.
Publicado: (2022)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide
por: Kikuchi, Taku, et al.
Publicado: (2017)

COVID-19 and Hyperinflammatory Syndrome in Children: Kawasaki Disease with Macrophage Activation Syndrome in Disguise?
por: Loomba, Rohit S, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

EP10 Hyperinflammatory syndrome in a patient with rheumatoid arthritis and COVID-19
por: Ong, Melissa, et al.
Publicado: (2020)

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
por: Webb, Brandon J, et al.
Publicado: (2020)

Hyperinflammatory shock in children during COVID-19 pandemic
por: Riphagen, Shelley, et al.
Publicado: (2020)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept
por: Choi, Rachel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s4asrru7svii7br6196dig5vpc